HW201877 is a drug which acts as a potent inhibitor of the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH). It increases levels of prostaglandin E2 and stimulates tissue regeneration, and has been researched in animal studies for treatment of conditions such as inflammatory bowel disease and idiopathic pulmonary fibrosis.